Abstract
AbstractThe ruxolitinib compassionate use (CU) program offered ruxolitinib to patients ≥2 years of age with confirmed steroid-resistant acute or chronic graft-versus-host disease (aGvHD and cGvHD, respectively). Data from 1180 patients (n = 775, 370 and 35 with cGvHD, aGvHD, and non-specified GvHD, respectively) were analyzed. Most patients had severe cGvHD (56%) or stage III/IV aGvHD (70%) disease and had previously received corticosteroids ( > 80%); ruxolitinib was requested primarily as a second-/third-line option. Patients <12 and ≥12 years old most often received the recommended ruxolitinib doses (5 mg twice daily [BID] and 10 mg BID, respectively); however, 23% and 30% of ≥12 year olds with cGvHD and aGvHD, respectively, received the lower dose of 5 mg BID. Notably, corticosteroid usage decreased with ruxolitinib treatment; at the initial ruxolitinib request, 81% and 91% of patients with cGvHD and aGvHD, respectively, were receiving corticosteroids whereas at resupply, 62% and 64%, respectively, were receiving corticosteroids. Eighty two percent of evaluable patients with cGvHD had a complete or partial response to treatment and 56% of evaluable patients with aGvHD had a best response of grade 0/I. These findings demonstrate the rapid and positive effects of ruxolitinib in patients with GvHD in a real-world setting.
Funder
Novartis Pharma AG, Basel, Switzerland
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N. Engl J Med. 2017;377:2167–79.
2. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38:305–10.
3. Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H, et al. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:1749–58.
4. Hamad N, Lachance S, De Courcy J, Rowaichi L, Zuurman M, Mohty M. Patient-Reported Outcomes in Acute Graft-Vs-Host Disease: Quality-Of-Life Findings from a Real-World Study. Bone Marrow Transplant. 2021;56:85–7.
5. Lachance S, Hamad N, De Courcy J, Gibson G, Zuurman M, Mohty M. Impact of Chronic Gvhd Severity and Steroid Response on the Quality of Life in Patients Following Allogeneic Stem Cell Transplantation: Findings from A Real-World Study. Bone Marrow Transplant. 2021;56:83–4.